What Lies Beneath the Stone? Metabolic Insights From Composition-Based Analysis of Kidney Stones

This retrospective observational study investigates the metabolic abnormalities associated with different types of kidney stones by analyzing their composition. The study includes adult patients diagnosed with urolithiasis, whose stone samples were analyzed using Fourier Transform Infrared (FTIR) spectroscopy. Clinical, biochemical, and 24-hour urine metabolic parameters were compared between first-time and recurrent stone formers, and among subtypes of calcium oxalate stones (monohydrate vs. dihydrate). The goal is to identify metabolic risk factors that contribute to stone formation and recurrence, and to provide insights for individualized prevention strategies.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Urolithiasis, Calcium Oxalate Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Male Urogenital Diseases Nephrolithiasis, Calcium Oxalate Urogenital Diseases Urolithiasis Urologic Diseases

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

About this study

This retrospective study aims to evaluate the metabolic characteristics of patients with urolithiasis based on kidney stone composition. Data were collected from patients treated for kidney stones between January 2010 and December 2024 at a tertiary urology center. Stone analysis was performed using FTIR spectroscopy, classifying stones into subtypes including calcium oxalate monohydrate (COM), calcium oxalate dihydrate (COD), uric acid, and mixed types.

Serum levels of calcium, phosphorus, uric acid, creatinine, and parathyroid hormone (PTH), along with 24-hour urine values (calcium, oxalate, citrate, uric acid, volume, and pH), were recorded. The study primarily compares metabolic differences between:

First-time vs. recurrent stone formers

COM vs. COD stone subtypes

Findings from this study are expected to improve understanding of metabolic risk factors and contribute to the development of tailored metabolic evaluations and dietary or pharmacological preventive strategies for recurrent stone formers.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age ≥ 18 years
Patients diagnosed with kidney stones between January 2010 and December 2024
Stone composition analyzed via Fourier-transform infrared (FTIR) spectroscopy
Available metabolic panel including serum and 24-hour urine values

Exclusion criteria

Patients with secondary hyperparathyroidism, renal tubular acidosis, or other systemic metabolic diseases affecting stone formation
Patients with incomplete medical records
Patients with non-calcium-based stones (e.g., uric acid, struvite, cystine)

Treatment and study plan

Metabolik taş analizi ile retrospektif gözlem

Other

This study did not involve an active intervention. It retrospectively analyzed medical records of 506 patients who underwent compositional analysis of kidney stones to identify metabolic abnormalities. The aim was to evaluate stone composition in relation to metabolic parameters such as serum and 24-hour urine values, without modifying patient treatment.

Other names: Böbrek taşı kompozisyonu değerlendirmesi Retrospektif metabolik değerlendirme

Primary outcomes

Kalsiyum oksalat taşı tipine göre serum ve 24 saatlik idrar parametrelerinin dağılımı Zaman Çerçevesi (Time Frame): 01 Ocak 2010 - 31 Aralık 2024 tarihleri arasında toplanan hasta verileri

Time frame: January 2010 and December 2024

FTIR spektroskopisi ile taş bileşimi belirlenen hastalar arasında, kalsiyum oksalat monohidrat (COM) ve dihidrat (COD) taşı olan bireylerin metabolik parametreleri (serum kalsiyum, fosfor, magnezyum, parathormon; 24 saatlik idrarla kalsiyum, oksalat, sitrat, pH, Na, ürik asit vb.) retrospektif olarak analiz edilmiştir.

Sponsors and collaborators

Lead sponsor

Hisar Intercontinental Hospital

Other

Registry information

Acronym: Kidney stone

Important dates

Study start: 2010
Primary completion: 2024
Study completion: 2024
First posted: May 28, 2025
Registry last updated: May 28, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed